Marketing Campaign
0102030405
🔬 I-124 Production with Cyclotron: Enabling Advanced Antibody Imaging
2026-03-25
In the era of precision medicine, monoclonal antibodies have become a cornerstone of modern cancer therapy.
A key question remains:
👉 How can we visualize where these antibodies go inside the body?
Immuno-PET provides a powerful answer — enabling non-invasive, whole-body imaging of target expression and drug distribution, supporting better patient selection and treatment decisions.
🚀 Why I-124?
¹²⁴I is recognized as one of the “next-generation PET radionuclides” recommended by the International Atomic Energy Agency (IAEA), alongside ⁶⁴Cu and ⁸⁹Zr.
With a half-life of ~4 days, it is well matched to the biological behavior of monoclonal antibodies, enabling extended observation and more flexible imaging schedules.
👉 Compared with conventional short-lived isotopes (e.g., ¹⁸F, ¹¹C), these solid-target radionuclides offer:
• Better alignment with antibody pharmacokinetics
• Longer imaging windows
• Multi-timepoint studies
• Greater flexibility in clinical and research workflows
In addition, their favorable positron emission characteristics further support reliable PET imaging performance.
⚙️ A Simpler and Practical Labeling Approach
One of the key advantages of ¹²⁴I lies in its direct labeling chemistry:
• No need for chelators
• Mild reaction conditions
• Covalent binding to antibody structures
👉 This helps preserve antibody integrity and simplifies the overall workflow.
🧪 Applications
¹²⁴I-labeled antibodies are widely used in:
Clinical applications
• Whole-body assessment of target expression
• Patient selection for targeted therapies
• Treatment monitoring
Research applications
• Antibody biodistribution studies
• Drug development and validation
• In vivo target engagement analysis
🌍 An Emerging Opportunity
Although ¹²⁴I shows strong potential, its production remains technically demanding, and only a limited number of institutions currently have the capability for routine production.
👉 This creates significant opportunities for cyclotron-based isotope platforms.
🔧 How LBT Supports I-124 Production
At Longevous Beamtech (LBT), we provide an integrated solution for iodine isotope production:
• Cyclotron systems - LB-20
• Solid target systems for stable irradiation
• Dry Distillation & Dissolution Module - for I-124 purification
• Radiochemistry modules for downstream processing
👉 In practical operation, one production batch can support 10+ patient studies under optimized conditions, making it well suited for both clinical use and research workflows.
💡 From research to clinical translation, ¹²⁴I is becoming a key isotope for antibody-based molecular imaging, supporting the future of precision medicine.